---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-199383"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:50:29.326077+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IO Biotech Q2 net loss $20.7M; cash runway into Q4 2025; Phase 3 interim analysis expected Q3 2024

## Summary
- Net loss of $20.7M for Q2 2024 vs $21.2M in Q2 2023; R&D expenses $15.8M.
- Cash and equivalents $100.7M at June 30, 2024, down from $143.2M at year-end 2023.
- Phase 3 trial (IOB-013) interim analysis for ORR expected Q3 2024; primary PFS endpoint in H1 2025.
- Potential BLA submission in Q4 2024 if interim analysis supports accelerated approval.
- Completed enrollment in Phase 2 basket trial (IOB-022) for NSCLC and SCCHN; data to be presented at ESMO.

## SEC filing metadata
- accession: 0001193125-24-199383
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312524199383/0001193125-24-199383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312524199383/d894513d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-199383
- JSON: https://secwatch.observer/filing/0001193125-24-199383.json
- Plain text: https://secwatch.observer/filing/0001193125-24-199383.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.